Koers Hangzhou Tigermed Consulting Co., Ltd OTC Markets
Aandelen
HNGZY
US41044T1088
Biotechnologie & Medisch Onderzoek
Vertraagde tijd
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
4,2 USD | -4,55% |
|
-.--% | -.--% |
14/06 | Tigermed Consulting verzekert normale bedrijfsvoering ondanks koersschommelingen | MT |
25/04 | Winst Hangzhou Tigermed Consulting 59% lager in Q1 | MT |
Omzet 2024 * | 7,94 mld. 1,09 mld. 1,02 mld. | Omzet 2025 * | 9,4 mld. 1,3 mld. 1,21 mld. | Marktkapitalisatie | 43,06 mld. 5,93 mld. 5,54 mld. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | 2,05 mld. 283 mln. 264 mln. | Nettowinst (verlies) 2025 * | 2,51 mld. 346 mln. 323 mln. | EV/omzet 2024 * | 4,66 x |
Nettoliquiditeiten 2024 * | 6,01 mld. 828 mln. 772 mln. | Nettoliquiditeiten 2025 * | 8,37 mld. 1,15 mld. 1,08 mld. | EV/omzet 2025 * | 3,69 x |
K/w-verhouding 2024 * |
22,7
x | K/w-verhouding 2025 * |
18,5
x | Werknemers | - |
Dividendrendement 2024 * |
0,94% | Dividendrendement 2025 * |
1,18% | Vrij verhandelbaar | 69,68% |
1 dag | -4,55% | ||
6 maanden | -46,02% |
![Extreem 4.2](/images/extremecours_fleche.png)
![Extreem 4.2](/images/extremecours_fleche.png)
![Extreem 4.2](/images/extremecours_fleche.png)
![Extreem 4.2](/images/extremecours_fleche.png)
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Xiao Chun Cao
CEO | Chief Executive Officer | 55 | 01-01-05 |
Hao Wu
PSD | President | 56 | 01-01-20 |
Xiao Ping Ye
CHM | Chairman | 61 | - |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Xiao Chun Cao
CEO | Chief Executive Officer | 55 | 01-01-05 |
Bing Hui Zhang
CHM | Chairman | 61 | 28-04-20 |
Xiao Ping Ye
CHM | Chairman | 61 | - |
![Consensus](/images/consensus_flch.gif)
Herzieningen van WPA
Vaira. 1 jan. | Kapi. | |
---|---|---|
+39,72% | 53,67 mld. | |
+33,67% | 38,86 mld. | |
-7,98% | 38,76 mld. | |
-10,77% | 27,27 mld. | |
+11,64% | 25,91 mld. | |
-17,15% | 20,29 mld. | |
+34,46% | 12,78 mld. | |
+29,48% | 12,18 mld. | |
-2,98% | 11,96 mld. |
- Beurs
- Aandelen
- Koers 300347
- Koers HNGZY